SIGA Delivers First Courses of Arestvyr(TM) Under BARDA Contract
NEW YORK, March 12, 2013 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (Nasdaq:SIGA), a company specializing in the development of pharmaceutical agents to fight pathogens capable of use as bioweapons, today announced the first of a series of deliveries of its proprietary smallpox antiviral drug, Arestvyr™, to the United States Government's Strategic National Stockpile under SIGA's contract with the Biomedical Advanced Research and Development Authority (BARDA).
"The men and women of SIGA are proud of their longstanding partnership with BARDA, taking this important step forward in protecting our fellow citizens against the threat of bioterrorism," declared Dr. Eric A. Rose, SIGA's Chairman and Chief Executive Officer. "This first commercial delivery marks a major milestone in SIGA's transformation from a research company to a commercial biopharmaceutical enterprise. While SIGA continues to research and develop pharmaceutical agents to fight other lethal pathogens, and concurrently seeks approval and licensing of Arestvyr from the U.S. Food and Drug Administration, this first delivery of Arestvyr to the Stockpile is evidence of our ability to oversee the manufacture and delivery of large quantities of high-quality pharmaceutical product. It gives us great confidence in SIGA's capabilities and aspirations, and moves us well down the path to generating substantial contractual payments from BARDA later this year and beyond."
BARDA, part of the Office of the Assistant Secretary for Preparedness and Response in the U.S. Department of Health and Human Services, provides an integrated, systematic approach to the development and purchase of the necessary vaccines, drugs, therapies, and diagnostic tools for public health emergencies. SIGA may begin to obtain payment under the BARDA contract once it has delivered 500,000 of the 2,000,000 contracted-for courses of Arestvyr. This first delivery of approximately 190,000 courses moves SIGA much closer to that moment.
Arestvyr (Tecovirimat) is one of the first novel drugs to be developed, procured and now delivered to the Strategic National Stockpile under the post-9/11 legislative authority known as Project BioShield. Developed to serve as a therapeutic drug for treatment of smallpox, whether resulting from a terrorist attack, biowarfare or a new natural outbreak, Arestvyr is an investigational new drug not yet approved or licensed as safe and effective by the U.S. Food and Drug Administration (FDA). Arestvyr was formerly known as ST-246®.
Recent SIGA News
- SIGA Technologies to Host Business Update Call on May 7 Following Release of First-Quarter 2024 Financial Results • GlobeNewswire Inc. • 05/01/2024 09:00:00 PM
- SIGA Amends International Promotion Agreement with Meridian to Enhance International Growth Opportunities of Oral TPOXX® • GlobeNewswire Inc. • 04/01/2024 08:05:00 PM
- SIGA Names Larry Miller General Counsel • GlobeNewswire Inc. • 03/25/2024 11:30:00 AM
- SIGA Reports Financial Results for Three and Twelve Months Ended December 31, 2023 • GlobeNewswire Inc. • 03/12/2024 08:05:00 PM
- SIGA Declares Special Cash Dividend of $0.60 Per Share • GlobeNewswire Inc. • 03/12/2024 11:30:00 AM
- SIGA Technologies to Host Business Update Call on March 12th, 2024 Following Release of Fourth Quarter and Full Year 2023 Financial Results • GlobeNewswire Inc. • 03/05/2024 12:30:00 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/01/2024 08:54:12 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/30/2024 10:04:04 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 01/30/2024 10:01:59 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/22/2024 09:01:28 PM
- SIGA Announces Appointment of Diem Nguyen, Ph.D., MBA, as New Chief Executive Officer • GlobeNewswire Inc. • 01/22/2024 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2024 01:49:12 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/07/2023 10:00:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/07/2023 09:05:39 PM
- SIGA Reports Financial Results for Three and Nine Months Ended September 30, 2023 • GlobeNewswire Inc. • 11/07/2023 09:05:00 PM
- SIGA Technologies to Host Business Update Call on November 7th, 2023 Following Release of Third Quarter 2023 Financial Results • GlobeNewswire Inc. • 10/26/2023 11:30:00 AM
- SIGA Announces Creation of Joint Procurement Mechanism by European Commission with Anticipated Initial Orders of Approximately $18 Million for Oral TPOXX® (Tecovirimat) by Participating Countries • GlobeNewswire Inc. • 10/23/2023 12:00:00 PM
- SIGA Technologies Names Dr. Jay K. Varma as EVP and Chief Medical Officer • GlobeNewswire Inc. • 09/06/2023 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/06/2023 10:05:19 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/08/2023 08:50:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2023 08:05:20 PM
- SIGA Reports Financial Results for Three and Six Months Ended June 30, 2023 • GlobeNewswire Inc. • 08/08/2023 08:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/28/2023 08:08:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/28/2023 11:08:07 AM
- SIGA Announces U.S. Government Procurement Orders of Approximately $138 Million for Oral and IV TPOXX® • GlobeNewswire Inc. • 07/27/2023 08:45:00 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM